VEDANTA BIOSCIENCES, INC.
Live Biotherapeutic Products using defined bacterial consortia for gastrointestinal diseases
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Latest Form D
- $107M, May 2023
- Total capital
- $309M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $210M
- 4 Form D · last May 2023
- 42 months since last filing
- Federal contracts
- $99.1M
- 1 award · Health and Human S
- Rank in Biotech#9 of 4373
- Granted patents
- 15
- 25 pending · first 2018
- Rank in peer group#112 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$107M
- Private capital raisedForm D · SEC · 3rd filing$68.4M
- Federal contractHealth and Human S · To Develop Medical Countermeasures (mcms) That Treat Antibiotic Resistant Infections.$99.1M
- Private capital raisedForm D · SEC · 2nd filing$8M
- Private capital raisedForm D · SEC · 1st filing$26.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#112 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Daniel L CoutoResearcherExecutive OfficerLinked by 2 patents
- Bennett ShapiroDirectorNamed in SEC Form D filings
- Bernat OlleExecutive Officer, DirectorNamed in SEC Form D filings
- Bharatt M. ChowriraDirectorNamed in SEC Form D filings
- Charles SherwoodDirectorNamed in SEC Form D filings
- Christopher ViehbacherDirectorNamed in SEC Form D filings
Show all 14 people
- Curt LaBelleDirectorNamed in SEC Form D filings
- Jeffrey SilberExecutive OfficerNamed in SEC Form D filings
- John L LaMattinaDirectorNamed in SEC Form D filings
- Mark MullikinExecutive OfficerNamed in SEC Form D filings
- Martin HeideckerDirectorNamed in SEC Form D filings
- Neil TiwariDirectorNamed in SEC Form D filings
- Susan DillonDirectorNamed in SEC Form D filings
- Troy IgnelziDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- GrantedCompositions And Methods For The Treatment Of AllergyUSPTOUS 12,582,679
- PendingTreatment Of Clostridium Difficile InfectionUSPTOApplication 19273369
- GrantedMethods And Compositions For Preserving BacteriaUSPTOUS 12,460,175
Show all 40 patent records
- Compositions And Methods For The Treatment Of AllergyMar 24, 2026 · US 12,582,679Granted
- Treatment Of Clostridium Difficile InfectionFeb 5, 2026 · Application 19273369Pending
- Methods And Compositions For Preserving BacteriaNov 4, 2025 · US 12,460,175Granted
- Treatment Of Clostridium Difficile InfectionAug 19, 2025 · US 12,390,498Granted
- Methods Of Decreasing Dysbiosis And Restoring A MicrobiomeMay 22, 2025 · Application 18932688Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsJan 9, 2025 · Application 18748761Pending
- Methods Of Decreasing Dysbiosis And Restoring A MicrobiomeDec 10, 2024 · US 12,161,680Granted
- Compositions And Methods For Treating CancerNov 7, 2024 · Application 18285548Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsSep 26, 2024 · Application 18277572Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsAug 6, 2024 · US 12,053,495Granted
- Methods Of Colonizing A Microbiome, Treating And/or Preventing Inflammatory Bowel Disease And Graft Versus Host DiseaseMay 30, 2024 · Application 18574232Pending
- Methods And Compositions For Preserving BacteriaNov 14, 2023 · US 11,814,615Granted
- Treatment Of Clostridium Difficile InfectionJul 18, 2023 · US 11,701,396Granted
- Compositions And Methods For Suppressing Pathogenic OrganismsDec 29, 2022 · Application 17633930Pending
- Methods And Compositions For Preserving BacteriaDec 8, 2022 · Application 17760674Pending
- Compositions And Methods For Enhancing Immune Checkpoint Inhibitor TherapyDec 1, 2022 · Application 17773863Pending
- Methods And Compositions For Preserving BacteriaSep 20, 2022 · US 11,447,738Granted
- Compositions And Methods For The Treatment Of AllergyMay 11, 2021 · US 11,000,556Granted
- Compositions And Methods For The Treatment Of CancerNov 26, 2020 · Application 16962274Pending
- Methods And Compositions For Determining Bacterial IntegrityFeb 27, 2020 · Application 16469742Pending
- Treatment Of Clostridium Difficile InfectionFeb 11, 2020 · US 10,555,980Granted
- Compositions And Methods For The Treatment Of AllergyDec 17, 2019 · US 10,507,221Granted
- Treatment Of Clostridium Difficile InfectionOct 29, 2019 · US 10,456,431Granted
- Treatment Of Clostridium Difficile InfectionJul 16, 2019 · US 10,350,250Granted
- Treatment Of Clostridium Difficile InfectionSep 4, 2018 · US 10,064,904Granted
- Treatment Of Clostridium Difficile InfectionJun 19, 2018 · US 9,999,641Granted
- Methods Of Decreasing Dysbiosis And Restoring A MicrobiomeApplication PCTUS2019046926Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsApplication 62884917Pending
- Methods Of Decreasing Dysbiosis And Restoring A MicrobiomeApplication 62829959Pending
- Methods Of Decreasing Dysbiosis And Restoring A MicrobiomeApplication 62829513Pending
- Methods Of Decreasing Dysbiosis And Restoring A MicrobiomeApplication 62815395Pending
- Compositions And Methods For The Treatment Of CancerApplication PCTUS2019014120Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsApplication PCTUS2018065031Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsApplication 62769461Pending
- Compositions And Methods For The Treatment Of AllergyApplication PCTUS2018060187Pending
- Methods For Assessing Colonization Of A MicrobiomeApplication 62724185Pending
- Compositions And Methods For The Treatment Of AllergyApplication 62721786Pending
- Methods of decreasing dysbiosis and restoring a microbiomeApplication 62765165Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsApplication 62703917Pending
- Compositions And Methods For Suppressing Pathogenic OrganismsApplication 62643554Pending
Related companies, and why
- Cellerant Therapeutics, Inc.Similar federal contract value in Biotech · $185M in contracts
- Sarepta TherapeuticsSimilar federal contract value in Biotech · $169M in contracts
- CELLPHIRE, INCSimilar federal contract value in Biotech · $162M in contracts
- CONTINUUS Pharmaceuticals, Inc.Similar federal contract value in Biotech · $73.7M in contracts
- GUILD ASSOCIATES INCSimilar federal contract value in Biotech · $69.6M in contracts
- Spero Therapeutics, Inc.Similar federal contract value in Biotech · $65.6M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .